Biogen upbeat on Tysabri progess
RTE.ie - Ireland
Biotechnology company Biogen Idec, Elan's partner for developing the Tysabri drug, has reported first quarter profit of $132m, with sales of its MS ...
See all stories on this topic

Market Report -- In Play (BIIB)
MSN Money - USA
Co reports 1Q07 Tysabri revs of $30 mln vs. $34.1 mln street expectation; reports 1Q07 Avonex WW revs of $449 mln vs. $441 mln street expectation. ...
See all stories on this topic

Biogen Idec Reports First Quarter 2007 Results
Genetic Engineering News (press release) - New Rochelle,NY,USA
Global in-market net sales of TYSABRI(R) (natalizumab) in the first quarter of 2007 were $48 million. Based on our collaboration structure with Elan, ...
See all stories on this topic